Komori
Tri Chemical Laboratories (4369) · FactHigher Research and Development Expenses for the Interim Period

Recognition of Research and Development Expenses

First written in FY2017-Q2. 11 of 37 entries say "Restated". Latest entry: FY2027-H1.

37entries
11years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseOtherFY2017-Q2 – FY2027-H12016: 22017: 420172018: 420182019: 420192020: 420202021: 420212022: 420222023: 420232024: 320242025: 220252026: 22026
Same theme, other companies
Continued company-wide R&D activities and resource investmentA theme 202 companies write about · 0 as a headwind · 215 as a tailwind

92 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 186 companies compared. The sentences above are computed from all 186.Comparing 200 of the theme's 217 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1Higher Research and Development Expenses for the Interim PeriodAnnual report

    「Total R&D expenses for the interim cumulative consolidated period were ¥373.452 million.」

    R&D expenses for the interim cumulative consolidated period were ¥373.452 million, up from ¥339.908 million in the same period of the previous year.
  2. FY2026Full-year decrease in R&D expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥606.097 million.」

    Full-year R&D expenses were ¥606.097 million, down from ¥665.655 million in the previous fiscal year.
  3. FY2026-H1Decline in R&D expenses for the interim periodAnnual report

    「R&D expenses 339.908 Same as above 294.060 Same as above」

    R&D expenses for the interim cumulative consolidated period were ¥294.060 million, down from ¥339.908 million in the same period of the previous year.
  4. FY2025Full-year decrease in R&D expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥660.653 million.」

    Full-year R&D expenses were ¥660.653 million, down from ¥665.655 million in the previous fiscal year.
  5. FY2025-H1Higher Research and Development Expenses for the Interim PeriodAnnual report

    「R&D expenses 318.802 Same as above 339.908 Same as above」

    R&D expenses for the interim cumulative consolidated period were ¥339.908 million, up from ¥318.802 million in the same period of the previous year.
  6. FY2025-Q1First-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the first quarter cumulative consolidated period were ¥161.051 million.」

    R&D expenses for the first quarter cumulative consolidated period were ¥161.051 million, up from ¥143.071 million in the same period of the previous year.
  7. FY2024Full-year increase in research and development expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥665.655 million.」

    Full-year R&D expenses were ¥665.655 million, up from ¥569.279 million in the previous fiscal year.
  8. FY2024-Q3Third-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the third quarter cumulative consolidated period were ¥489.495 million.」

    R&D expenses for the third quarter cumulative consolidated period were ¥489.495 million, up from ¥409.225 million in the same period of the previous year.
  9. FY2024-Q2Second-quarter increase in R&D expensesAnnual report

    「R&D expenses 264.722 Same as above 318.802 Same as above」

    R&D expenses for the second quarter cumulative consolidated period were ¥318.802 million, up from ¥264.722 million in the same period of the previous year.
  10. FY2024-Q1First-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the first quarter cumulative consolidated period were ¥143.071 million.」

    R&D expenses for the first quarter cumulative consolidated period were ¥143.071 million, up from ¥122.678 million in the same period of the previous year.
  11. FY2023Full-year increase in research and development expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥569.279 million.」

    Full-year R&D expenses were ¥569.279 million, up from ¥486.067 million in the previous fiscal year.
  12. FY2023-Q3Third-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the third quarter cumulative consolidated period were ¥409.225 million.」

    R&D expenses for the third quarter cumulative consolidated period were ¥409.225 million, up from ¥368.184 million in the same period of the previous year.
  13. FY2023-Q2Second-quarter increase in R&D expensesAnnual report

    「R&D expenses 253.677 Same as above 264.722 Same as above」

    R&D expenses for the second quarter cumulative consolidated period were ¥264.722 million, up from ¥253.677 million in the same period of the previous year.
  14. FY2023-Q1First-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the first quarter cumulative consolidated period were ¥122.678 million.」

    R&D expenses for the first quarter cumulative consolidated period were ¥122.678 million, up from ¥122.322 million in the same period of the previous year.
  15. FY2022Full-year increase in research and development expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥486.067 million.」

    Full-year R&D expenses were ¥486.067 million, up from ¥452.480 million in the previous fiscal year.
  16. FY2022-Q3Third-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the third quarter cumulative consolidated period were ¥368.184 million.」

    R&D expenses for the third quarter cumulative consolidated period were ¥368.184 million, up from ¥357.820 million in the same period of the previous year.
  17. FY2022-Q2Second-quarter increase in R&D expensesAnnual report

    「Total R&D expenses for the second quarter cumulative consolidated period were ¥253.677 million.」

    R&D expenses for the second quarter cumulative consolidated period were ¥253.677 million, up from ¥246.677 million in the same period of the previous year.
  18. FY2022-Q1First-quarter decrease in R&D expensesAnnual report

    「Total R&D expenses for the first quarter cumulative consolidated period were ¥122.322 million.」

    R&D expenses for the first quarter cumulative consolidated period were ¥122.322 million, down from ¥125.625 million in the same period of the previous year.
  19. FY2021Full-year decrease in R&D expensesAnnual report

    「Total R&D expenses incurred by the Group during the consolidated fiscal year were ¥452.480 million.」

    Full-year R&D expenses were ¥452.480 million, down from ¥484.682 million in the previous fiscal year.
  20. FY2021-Q3Third-quarter increase in research and development expensesAnnual report

    「Total R&D expenses for the third quarter cumulative consolidated period were ¥357.820 million.」

    R&D expenses for the third quarter cumulative consolidated period were disclosed at ¥357.820 million, up from ¥294.747 million in the same period of the previous year.
  21. FY2021-Q2Second-quarter increase in research and development expensesAnnual report

    「Total research and development expenses for the cumulative period of the second quarter on a consolidated basis were ¥246.677 million.」

    Total R&D expenses for the second quarter cumulative consolidated period were ¥246.677 million, up from ¥227.442 million in the same period of the previous year.
  22. FY2021-Q1First-quarter increase in research and development expensesAnnual report

    「Total research and development expenses for the cumulative period of the first quarter on a consolidated basis were ¥125.625 million.」

    The company disclosed total consolidated research and development expenses of ¥125.625 million for the cumulative period of the first quarter, an increase from ¥113.203 million in the same period of the previous fiscal year.
  23. FY2020Full-year increase in research and development expensesAnnual report

    「Total research and development expenses incurred by the Group during the consolidated fiscal year were ¥484.682 million.」

    Full-year research and development expenses were ¥484.682 million, an increase from ¥408.913 million in the previous fiscal year.
  24. FY2020-Q3Third-quarter increase in research and development expensesAnnual report

    「Total research and development expenses for the cumulative period of the third quarter on a consolidated basis were ¥363.908 million.」

    The company disclosed total consolidated research and development expenses of ¥363.908 million for the cumulative period of the third quarter, an increase from ¥294.747 million in the same period of the previous fiscal year.
  25. FY2020-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative period of the second quarter on a consolidated basis were ¥227.442 million.」

    The company disclosed total consolidated research and development expenses of ¥227.442 million for the cumulative period of the second quarter.
  26. FY2020-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative period of the first quarter on a consolidated basis were ¥113.203 million.」

    The company disclosed total consolidated research and development expenses of ¥113.203 million for the cumulative period of the first quarter.
  27. FY2019Full-year increase in research and development expensesAnnual report

    「Total research and development expenses incurred by the Group during the consolidated fiscal year were ¥408.913 million.」

    The company disclosed full-year research and development expenses of ¥408.913 million. A simple comparison with the previous fiscal year's ¥302.414 million was not made because the scope of consolidation differed.
  28. FY2019-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative period of the third quarter on a consolidated basis were ¥294.747 million.」

    The company disclosed total consolidated research and development expenses of ¥294.747 million for the cumulative period of the third quarter.
  29. FY2019-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative period of the second quarter on a consolidated basis were ¥178.96 million.」

    The company disclosed total consolidated research and development expenses of ¥178.96 million for the cumulative period of the second quarter.
  30. FY2019-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative period of the first quarter on a consolidated basis were ¥84.929 million.」

    The company disclosed total consolidated research and development expenses of ¥84.929 million for the cumulative period of the first quarter.
  31. FY2018RestatedAnnual report

    「Total research and development expenses incurred by the company during the fiscal year were ¥302.414 million.」

    The company disclosed full-year research and development expenses of ¥302.414 million.
  32. FY2018-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative period of the third quarter were ¥234.962 million.」

    The company disclosed total research and development expenses of ¥234.962 million for the cumulative period of the third quarter.
  33. FY2018-Q2RestatedAnnual report

    「Total research and development expenses for the cumulative period of the second quarter were ¥157.642 million.」

    The company disclosed total research and development expenses of ¥157.642 million for the cumulative period of the second quarter.
  34. FY2018-Q1RestatedAnnual report

    「Total research and development expenses for the cumulative period of the first quarter were ¥87.733 million.」

    The company disclosed total research and development expenses of ¥87.733 million for the cumulative period of the first quarter.
  35. FY2017RestatedAnnual report

    「Total research and development expenses incurred by the company during the fiscal year were ¥363.641 million.」

    The company disclosed full-year research and development expenses of ¥363.641 million.
  36. FY2017-Q3RestatedAnnual report

    「Total research and development expenses for the cumulative period of the third quarter were ¥283.201 million.」

    The company disclosed total research and development expenses of ¥283.201 million for the cumulative period of the third quarter.
  37. FY2017-Q2First statedAnnual report

    「Total research and development expenses for the cumulative second quarter under review were ¥175,742 thousand.」

    The disclosure reports total research and development expenses for the cumulative second quarter under review.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Tri Chemical Laboratories yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Recognition of Research and Development Expenses | Tri Chemical Laboratories Inc. (4369) | Komori